Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.6 HKD | +2.84% | +11.54% | -6.90% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 12.89 for the current year and 10.18 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.90% | 1.03B | - | ||
+12.07% | 128B | A- | ||
-9.04% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+16.72% | 7.19B | C | ||
+25.15% | 4.99B | B+ | ||
+7.17% | 3.4B | C- | ||
-1.36% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1858 Stock
- Ratings Beijing Chunlizhengda Medical Instruments Co., Ltd.